Small Molecule Kinase Inhibitors

Content

• I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
• II. EXECUTIVE SUMMARY
• 1.INDUSTRY OVERVIEW
  • Kinase Inhibitors Industry: A Prelude
  • Understanding Kinase Inhibitors
  • Drug Development Interest in Kinase Inhibitors Soars
  • Table 1: Clinical Phase Transition Percentage for Novel Kinase Inhibitor Compounds in Clinical Development - All Drugs Vs Kinase Inhibitors, During the Period (1995-2007) (includes corresponding Graph/Chart)
  • Protein Kinases As Potential Drug Targets: Opportunities Abound
  • Kinase Profiling: The Backbone for pKi Drug Development
  • Developing Kinase Inhibitors
  • Kinase Inhibitors: Huge Potential Envisaged in the Treatment of Cancer
  • Rising Incidences of Cancer & Unmet Treatment Needs: A Prime Driver
  • Table 2: Global New Cases Registered and Total number of Deaths Resulting From Cancer (2007): Breakdown by Male and Female (In Million)
  • In the Cancer End-Use Market Growth Fundamentals Get Stronger
  • Interest in Non-Cancer Therapies Gains Traction
  • Multi-Targeted Kinase Inhibitors: The Next Frontier
  • Rising Incidences of Resistance Sparks Interest in Combination Drug Therapies
  • Single Vs Multi-Target Kinase Inhibitor Drugs
  • Tough Regulatory Riders Threaten to Slow Down Number of Approvals
  • Spiraling Cost of Next Generation Cancer Drugs: A Cause for Concern
  • Table 3: Average Monthly Costs of Anti-Cancer Drugs (2007): Breakdown of Treatment Costs by Cancer Drug Brands - Rituxan, Erbitux, Revilimid, Avastin - High Dose, Avastin - Low Dose, Nexavar, Sutent, Herceptin, Gleevec, Tarceva, Tykerb, Iressa, Vectibix, Torisel and Targeted Therapies (In US$) for US, EU and Japan
  • Adequate Reimbursements: Critical to Product Success in the Marketplace
  • The Truth Behind Inadequate Reimbursement of New Cancer Drugs
  • Manufacturers Find Risk-Sharing, Rebating, & Contracting As Effective Antidotes
  • Financial-based Contracts
  • Performance-based Contracts
  • Reimbursements Issues in UK
  • On Cards: Reimbursement for Pfizer's Sutent in UK
  • Reimbursement for GlaxoSmithKline's Tyverb Hits a Roadblock in UK
  • Reimbursements Issues in the United States
  • Medicare Shifts Oral Anti Cancer Drugs to Higher Drug Formulary Tiers
  • Implications for the Patient
  • Table 4: Oral Anticancer Drugs Covered in Medicare Part D Plans (2009): Percentage Share Breakdown of Plans, Which Require Prior Authorization, & Plans, Which Have Quantity Limits, by Drug Brand (includes corresponding Graph/Chart)
  • Table 5: Oral Anticancer Drugs Covered in Medicare Part D Plans (2009): Breakdown of Cost Sharing Range by Drug Brand
  • Table 6: Placement of Select Oral Anticancer Drugs in the Drug Tier System Covered in Medicare Part D Plans for the Year 2009)
  • Transition of Oral Anti-Cancer Drugs to Higher Cost Sharing Tiers: Gleevec A Case in Point:
  • Table 7: Percentage Breakdown of Beneficiaries Prescribed Gleevec and Covered Under Standalone Prescription Drug Plans (PDPs) by Tier For Years 2006 through 2009 (includes corresponding Graph/Chart)
  • Table 8: Change in Percentage of Co-insurance Amount for Leading Oral Cancer Therapies Under Standalone Prescription Drug Plans (PDPs) (During 2006 to 2009) ??